Description
20mg is supplied as four separate 5mg vials to enhance stability. Reconstituting each vial only when needed helps maintain purity and allows for easier, more precise volume preparation.
Administered via once-weekly subcutaneous injection, it mimics the hormone amylin to delay gastric emptying and increase satiety via the brain’s hypothalamus.
- Mechanism: As an amylin analogue, it works differently from GLP-1 receptors, making it a valuable agent that can be used alone or in combination with semaglutide (known as CagriSema) for enhanced weight loss.
- Weight Loss Potential: In studies, cagrilintide has demonstrated substantial weight loss, with a Phase 3 trial (REDEFINE 1) showing a 11.8% reduction in body weight compared to 2.3% for placebo over 68 weeks.
- Appetite Control: It targets multiple mechanisms, including reducing cravings and slowing gastric emptying to manage food intake.
- Combination Treatment: Frequently studied with semaglutide (2.4 mg) to create a dual approach that targets both food intake (appetite) and metabolic health, often resulting in greater efficacy than either drug alone.
Side Effects: The most common side effects reported are gastrointestinal, such as nausea or constipation, similar to other peptide therapies that affect the gut-brain axis.
Cagrilintide is considered a “next-generation” weight loss peptide designed to work alongside, rather than just compete with, existing GLP-1 therapies to help patients reach and maintain lower HbA1c and weight levels.
Disclaimer: This information is for educational purposes based on research studies and does not constitute medical advice. Consult a healthcare provider before starting any peptide therapy.
Reviews
There are no reviews yet.